BioSpace News Archive

Drug Development

Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer

IMUNON, Inc. (NASDAQ: IMNN) announces that Memorial Sloan Kettering Cancer Center has joined MD Anderson Cancer Center in enrolling patients in a Phase 1/2 clinical trial evaluating IMUNON’s IMNN-001 in combination with bevacizumab in patients with advanced ovarian cancer.

February 27, 2024

·

6 min read

Business

Cryoport to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024

Cryoport, Inc. today announced that the Company will report financial results for the fourth quarter and year ended December 31, 2023 on Tuesday, March 12, 2024 after U.S. markets close.

February 27, 2024

·

4 min read

Genetown

Sengenics Corporation Announces Key Distributor in China

Sengenics Corporation LLC , a pioneer in the field of immunoproteomic biomarker discovery, proudly announces that it has entered into a sales distribution and services agreement with Chinese distributor Shanghai Universal Biotech Co., Ltd. (“UniV”).

February 27, 2024

·

2 min read

Biotech Beach

Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences

Evolus, Inc. today announced that members of its management team will present at the following investor conferences in March.

February 27, 2024

·

1 min read

Devonian Announces that its Subsidiary, Altius, Launches Authorized Generic of Dexlansoprazole (Dexilant®) in Canada

Devonian Health Group Inc. is pleased to announce that its wholly-owned subsidiary, Altius Healthcare Inc. has launched the first authorized generic of dexlansoprazole (Dexilant®) in Canada to treat symptoms of gastroesophageal reflux disease (GERD).

February 27, 2024

·

5 min read

Deals

NRx Pharmaceuticals, Inc. Announces Pricing of $1.5 Million Underwritten Public Offering of Common Stock Together with investor Commitment for Additional $1 million

NRx Pharmaceuticals, Inc. today announced the pricing of its underwritten public offering of shares of its common stock (or pre-funded warrants in lieu thereof) at a public offering price of $0.30 per share.

February 27, 2024

·

7 min read

Biotech Beach

Avidity Biosciences to Participate in Upcoming March 2024 Investor Conferences

Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that Avidity management will be participating at the following upcoming conferences.

February 27, 2024

·

1 min read

Business

Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise

Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced the reappointment of Cintia Piccina as Chief Commercial

February 27, 2024

·

5 min read

Business

PharmaDrug Appoints Current Board Member Dr. David Kideckel as Chairman

PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company”), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines

February 27, 2024

·

7 min read

Greg Merril Joins Simmbion as Executive Director in Support of Founding CEO Derese Getnet

Simmbion, The Living Medicine Company™, is excited to announce that Greg Merril has been appointed as Executive Director, joining the pioneering team led by Founding CEO

February 27, 2024

·

4 min read